Trump Signals Cannabis Rescheduling: What Schedule III Means

In December 2025, the U.S. cannabis world, from patients and advocates to investors and policymakers, saw a convergence of high-profile federal drug policy movements. As President Trump hinted he’s “very strongly” considering an executive order to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, federal regulators also took dramatic aim at opioids, designating fentanyl as a weapon of mass destruction in a separate executive action.

These developments reflect a broader shift in how the federal government conceptualizes drug policy, demonstrating a hardline stance on lethal synthetic opioids with a loosening of restrictions on cannabis, long stigmatized and federally illegal despite widespread state legalization and significant evidence of medical utility.

What Trump Is Proposing and What It Really Means

Around mid-December 2025, President Trump publicly acknowledged that he’s considering directing federal agencies to pursue rescheduling cannabis to Schedule III, the same category as some prescription painkillers and steroid treatments. Let’s review what this means.

Cannabis Today: Why Cannabis Is Still Schedule I Federally

Under federal law, cannabis is currently a Schedule I controlled substance. This is the most restrictive classification, shared with heroin and LSD, indicating no accepted medical use and high potential for abuse.

This classification has long put the U.S. at odds with state governments, where medical cannabis is legal in 42 states and Washington, D.C., and recreational use is legal in many jurisdictions. Advocates have slammed Schedule I as outdated and scientifically unsupported, particularly given extensive research showing therapeutic applications, especially for pain, epilepsy, PTSD, and other conditions.

Schedule III: Federal Recognition, But Not Legalization

Rescheduling to Schedule III would not legalize cannabis at the federal level, nor would it decriminalize possession or use nationwide. But it would:

• Acknowledge accepted and well-documented medical use, removing cannabis from the strictest regulatory category.
• Unlock broader scientific research, long hampered by federal red tape and stringent licensing.
• Lift the 280E federal tax penalty that currently prevents cannabis businesses from deducting ordinary business expenses.
• Improve access to capital and banking, potentially allowing broader institutional investment.

While rescheduling would be a meaningful policy shift, it does not equal legalization.

Market Reaction to Rescheduling Cannabis

News of a potential rescheduling announcement triggered dramatic movements in the financial markets. Cannabis stocks rallied on optimism:

• Tilray Brands (TLRY )shares jumped more than 20–40 % on various news days.
• Canopy Growth (CGC ) similarly saw double-digit gains.
• Cannabis ETFs like CNBS and MSOS also posted record spikes as traders priced in potential tax and regulatory benefits for the sector.

Investors are betting that shifting cannabis to Schedule III would lower federal tax burdens and open banking opportunities, making the industry more attractive to institutional capital. However, this optimism has been tempered at times by uncertainty and volatility, with some days seeing stocks retreat as traders grapple with the reality that no formal rulemaking has yet occurred.

Fentanyl as a “Weapon of Mass Destruction”: What It Signals

Simultaneously, the Trump administration issued a high-impact executive order designating fentanyl as a weapon of mass destruction, a symbolic and legal step allowing for more aggressive prosecution and international action against foreign producers and traffickers.

This action frames the administration’s approach to drug policy as one that differentiates sharply between harmful synthetic opioids and cannabis, which many view and research backs as a potential medical alternative. Advocates point to research suggesting that legal access to cannabis can reduce opioid use and overdose deaths, an argument bolstered by data showing decreases in opioid prescriptions where medical cannabis is available.

This dual narrative of cracking down on opioids while relaxing cannabis restrictions reflects a complex strategy aiming to support medical research and potentially reduce reliance on high-risk pharmaceuticals.

Is Schedule III the Right Move?

While rescheduling to Schedule III would represent the most significant federal cannabis policy reform in decades, advocates argue that it’s still not enough. Here’s why:

Schedule III Is Still Controlled and Restricted

Even Schedule III substances are regulated under federal law. This means cannabis could be subject to prescription requirements, potentially limiting access outside medical settings. Traditional dispensaries could also face pressure to transition into pharmaceutical outlets or risk losing relevance and recreational users would still be breaking federal law.

Unlike descheduling, which means removing cannabis entirely from the Controlled Substances Act, rescheduling maintains a federal framework that can restrict access, research parameters, and commercial freedom.

Pharmaceutical Capture Is a Real Risk

By categorizing cannabis alongside prescription drugs, the federal government implicitly signals that cannabis belongs in a pharmaceutical model. This shift could benefit large pharmaceutical companies that have the infrastructure to conduct clinical trials, manufacture standardized products, and navigate FDA pathways. On the other hand, it could also threaten the ability of patients to get the amount of cannabis medicine and route of administration they truly need. Additionally, physicians, medical staff, and pharmacists would need extensive training that is not yet available.

This kind of “pharma capture” risks consolidating the cannabis market in the hands of large corporations and undermining the diversity of products and access models that have emerged under state legalization.

Patients and Social Equity Still Suffer

Schedule III status, while medically recognizing cannabis does not erase decades of criminal justice impacts, nor does it automatically create equitable access for patients, veterans, or communities disproportionately harmed by prohibition.

Full descheduling is the end goal for many advocates because it:

• Removes federal criminal penalties.
• Aligns federal law with state legalization.
• Preserves access through dispensaries rather than only through doctors and pharmacies.
• Creates a regulatory framework centered on consumer safety, equity, and local economic opportunity.

Looking Ahead: Policy, Politics, and Public Health

As of late December 2025, no final action has yet been published in the Federal Register, and the rescheduling process still requires formal administrative rulemaking.

Still, Trump’s statements and the executive order dynamics reflect a growing acknowledgment among federal leaders, across partisan lines, that cannabis’s classification is outdated and that reform could yield public health and economic benefits.

But the conversation cannot stop with Schedule III. Full descheduling, coupled with thoughtful federal regulation and support for state programs, remains essential to ensure that cannabis policy serves patients, protects consumers, and empowers diverse communities rather than concentrating power in pharmaceutical or corporate hands.